Hal Barron has detailed efforts to embolden GlaxoSmithKline scientists to take “smart risks” when developing drugs. The culture change is part of an effort to stop the fear of failure from pushing GSK researchers to make conservative decisions.
Talking to the Financial Times, Barron discussed how rewarding teams that take molecules deep into the clinic and penalizing those that kill off assets early can subtly influence the interpretation of data.
“Once you start fearing failure, you become so conservative that you end up basically moving towards things that are obviously going to work and therefore likely to be not very innovative. And, ultimately, it’s a death spiral,” Barron said.
To cut the risk of such conservatism, Barron is encouraging staff to take more risks. Decisions about whether a risk is justified now falls on the individual who is in charge of a particular program. Before Barron’s arrival, GSK made decisions about whether to advance or drop a drug by consensus.
Ultimately, Barron hopes to double the proportion of development programs that end in approved drugs. Technology, notably artificial intelligence, is central to GSK’s efforts to boost productivity.
If successful, Barron’s attempts to cut the failure rate could transform GSK, but the timelines involved in drug development mean the payoff from the reform agenda is unlikely to come quickly. With investors pressuring GSK to improve now, Barron and his colleagues need some near-team successes to appease people.
Barron thinks GSK’s pipeline features drugs capable of boosting GSK’s near-term prospects. GSK’s $5.1 billion purchase of Tesaro gave it control of PARP inhibitor Zejula and anti-PD-1 antibody dostarlimab, teeing it up to make inroads into the ovarian and endometrial cancer markets. Additionally, its internal team has taken anti-BCMA antibody-drug conjugate GSK2857916 to the cusp of a filing for approval.
By Nick Paul Taylor
Source: Fierce Biotech
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.